Thomas Rowe
8Patents
2h-index
10Co-inventors
48Inventor score
Filing activity: Sep 8, 1997 → May 21, 2018
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US6090619A | Materials and methods for intracellular delivery of biologically active molecules | Emerging Cross-Sectional Technologies | 9 | Expired |
| US6171863A | Materials and methods for intracellular delivery of biologically active molecules | Emerging Cross-Sectional Technologies | 3 | Expired |
| US8987241B2 | Time-release and micro-dose formulations for topical application of estrogen and estrogen analogs or other estrogen receptor modulators in the treatment of dry eye syndrome, and methods of preparation and application | Human Necessities | 1 | Active |
| US8623854B2 | Nuclear export inhibitors of topoisomerase II alpha | Chemistry; Metallurgy | 1 | Active |
| US6627618B2 | Materials and methods for intracellular delivery of biologically active molecules | Emerging Cross-Sectional Technologies | 1 | Expired |
| US9616051B2 | Drug targets to overcome de novo drug-resistance in multiple myeloma | Chemistry; Metallurgy | 0 | Active |
| US10821092B2 | Viscous topical ocular formulations | Human Necessities | 0 | Active |
| US10799446B2 | Time-release and micro-dose formulations for topical application of estrogen and estrogen analogs or other estrogen receptor modulators in the treatment of dry eye syndrome, and methods of preparation and application | Human Necessities | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.